Compare LGN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGN | EWTX |
|---|---|---|
| Founded | 1963 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2025 | 2021 |
| Metric | LGN | EWTX |
|---|---|---|
| Price | $48.45 | $29.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $43.43 | $34.13 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 11-14-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,361,064,000.00 | N/A |
| Revenue This Year | $17.08 | N/A |
| Revenue Next Year | $32.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.19 | N/A |
| 52 Week Low | $26.96 | $10.60 |
| 52 Week High | $50.20 | $30.48 |
| Indicator | LGN | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 65.13 |
| Support Level | N/A | $25.92 |
| Resistance Level | N/A | $28.29 |
| Average True Range (ATR) | 0.00 | 1.54 |
| MACD | 0.00 | 0.44 |
| Stochastic Oscillator | 0.00 | 95.18 |
Legence Corp is a provider of engineering, installation and maintenance services for mission-critical systems in buildings. It focuses on high-growth sectors that have technically demanding buildings, including technology, life sciences, healthcare and education. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting and building controls in existing facilities to make them more energy efficient and sustainable.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.